Xiaoxia Jia1,2, Ting Guo2, Zhemin Li3, Meng Zhang1, Yi Feng1, Bin Dong4, Zhongwu Li4, Ying Hu5, Ziyu Li3, Xiaofang Xing2, Shuqin Jia1, Jiafu Ji1,2,3,5. 1. Department of Molecular Diagnosis, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China. 2. Department of Gastrointestinal Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China. 3. Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China. 4. Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China. 5. Biobank, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Abstract
BACKGROUND: Epstein-Barr virus-associated gastric cancer(EBVaGC)has a unique tumor immune microenvironment. We performed a comprehensive analysis of the tumor-infiltrating immune cells in a cohort of EBVaGC in a Chinese population. METHODS: Epstein-Barr encoding region (EBER) in situ hybridization was performed in 1,328 consecutive cases of surgically resected GC. Densities of immune cells, including T cells, B cells, natural killer cells, and macrophages from the patients were calculated after immunohistochemical staining with CD3, CD20, CD57, and CD68 antibodies in tissue microarrays, respectively. RESULTS: EBVaGC patients accounted for 4.1% (55 of 1,328) cases in the overall population. The average age of patients with EBVaGC was lower than that of non-EBVaGC patients. Histologically, EBVaGC patients exhibited poorly differentiated adenocarcinoma (P = 0.004) and lower frequency of vascular invasion (P = 0.034). The density of CD3+ T lymphocytes (CD3, 23.84 ± 14.49 vs. 12.76 ± 8.93, P < 0.001) and CD68+ macrophages (CD68, 9.73 ± 5.25 vs. 5.44 ± 4.18, P < 0.001) was significantly higher in EBVaGC patients. CD3+ T cell density predicted better 5-year overall survival of EBVaGC patients (P = 0.022). CONCLUSIONS: EBVaGC patients were younger with low-differentiated adenocarcinoma and less vascular invasion. Increased infiltration of multiple immune cells affected the prognosis of patients, especially EBVaGC patients with more CD3+ T lymphocytes, who survived longer.
BACKGROUND: Epstein-Barr virus-associated gastric cancer(EBVaGC)has a unique tumor immune microenvironment. We performed a comprehensive analysis of the tumor-infiltrating immune cells in a cohort of EBVaGC in a Chinese population. METHODS: Epstein-Barr encoding region (EBER) in situ hybridization was performed in 1,328 consecutive cases of surgically resected GC. Densities of immune cells, including T cells, B cells, natural killer cells, and macrophages from the patients were calculated after immunohistochemical staining with CD3, CD20, CD57, and CD68 antibodies in tissue microarrays, respectively. RESULTS: EBVaGC patients accounted for 4.1% (55 of 1,328) cases in the overall population. The average age of patients with EBVaGC was lower than that of non-EBVaGC patients. Histologically, EBVaGC patients exhibited poorly differentiated adenocarcinoma (P = 0.004) and lower frequency of vascular invasion (P = 0.034). The density of CD3+ T lymphocytes (CD3, 23.84 ± 14.49 vs. 12.76 ± 8.93, P < 0.001) and CD68+ macrophages (CD68, 9.73 ± 5.25 vs. 5.44 ± 4.18, P < 0.001) was significantly higher in EBVaGC patients. CD3+ T cell density predicted better 5-year overall survival of EBVaGC patients (P = 0.022). CONCLUSIONS: EBVaGC patients were younger with low-differentiated adenocarcinoma and less vascular invasion. Increased infiltration of multiple immune cells affected the prognosis of patients, especially EBVaGC patients with more CD3+ T lymphocytes, who survived longer.
Authors: H K Angell; J Lee; K-M Kim; K Kim; S-T Kim; S H Park; W K Kang; A Sharpe; J Ogden; A Davenport; D R Hodgson; J C Barrett; E Kilgour Journal: Oncoimmunology Date: 2018-12-10 Impact factor: 8.110
Authors: V Gambardella; J Castillo; N Tarazona; F Gimeno-Valiente; C Martínez-Ciarpaglini; M Cabeza-Segura; S Roselló; D Roda; M Huerta; A Cervantes; T Fleitas Journal: Cancer Treat Rev Date: 2020-03-23 Impact factor: 12.111
Authors: Anshuman Panda; Janice M Mehnert; Kim M Hirshfield; Greg Riedlinger; Sherri Damare; Tracie Saunders; Michael Kane; Levi Sokol; Mark N Stein; Elizabeth Poplin; Lorna Rodriguez-Rodriguez; Ann W Silk; Joseph Aisner; Nancy Chan; Jyoti Malhotra; Melissa Frankel; Howard L Kaufman; Siraj Ali; Jeffrey S Ross; Eileen P White; Gyan Bhanot; Shridar Ganesan Journal: J Natl Cancer Inst Date: 2018-03-01 Impact factor: 13.506
Authors: Shuting Han; Joshua K Tay; Celestine Jia Ling Loh; Axel Jun Ming Chu; Joe Poh Sheng Yeong; Chwee Ming Lim; Han Chong Toh Journal: Front Immunol Date: 2021-12-10 Impact factor: 7.561